Results 161 to 170 of about 2,895 (208)

Histopathological lesions of the gastrointestinal tract associated with the use of polystyrene sulfonate and sevelamer: a meta-analysis. [PDF]

Pathologica
Di Rienzo G, Crafa P, Delsante M, Fiaccadori E, Pedrazzi G, Campanini N, Corradini E.   +6 more
europepmc   +1 more source

Sucroferric oxyhydroxide monotherapy for hyperphosphatemia in Indian chronic kidney disease patients undergoing hemodialysis: A phase IV, single-arm, open-label study. [PDF]

World J Nephrol
Niranjan MR, Srinivasa S, Gupta V, Bhalla AK, Gaikwad A, Wangikar P, Suryawanshi S, Gajbe P.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sevelamer Carbonate

Annals of Pharmacotherapy, 2010
OBJECTIVE To review the pharmacology, pharmacokinetics, clinical efficacy, safety data, and place in therapy of sevelamer carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). DATA SOURCES A literature search of MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations Databases (1966-August 2009) was ...
Mary M, Barna, Toros, Kapoian, Neeta Bahal, O'Mara   +2 more
openaire   +4 more sources

Comparison of Sevelamer Hydrochloride and Sevelamer Carbonate: Risk of Metabolic Acidosis and Clinical Implications

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
Hyperphosphatemia is highly prevalent in patients with chronic kidney disease (CKD), particularly in those with advanced or end‐stage renal disease. Sevelamer hydrochloride is an ion‐exchange resin that reduces serum phosphorus concentrations. The agent also produces favorable lipid profile effects and does not cause hypercalcemia.
Ashwini B, Pai, Brian M, Shepler
openaire   +4 more sources

Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease

Drugs, 2014
Sevelamer carbonate (Renvela(®)), a buffered form of sevelamer hydrochloride (Renagel(®)), is an orally administered non-absorbed phosphate-binding anion exchange resin used in the treatment of hyperphosphataemia in chronic kidney disease (CKD). In the EU, sevelamer carbonate is approved in adult CKD patients who require dialysis and in those who do ...
Caroline M, Perry, Greg L, Plosker
openaire   +4 more sources

Does Concomitant Administration of Sevelamer and Calcium Carbonate Modify the Control of Phosphatemia?

Therapeutic Apheresis and Dialysis, 2010
AbstractThere is no guideline regarding the concomitant or distant administration of sevelamer and calcium carbonate. Our aim was to determine whether serum phosphate varied when sevelamer and calcium carbonate were administered concomitantly in comparison to administration at separate meals. Fourteen chronic hemodialysis patients were enrolled in this
Georges, Ouellet, Héloïse, Cardinal, Marjolaine, Mailhot, Louis-Georges, Ste-Marie, Louise, Roy   +4 more
openaire   +4 more sources

Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial

American Journal of Kidney Diseases, 2019
Hyperphosphatemia is associated with increased risk for chronic kidney disease (CKD) progression and reduced antiproteinuric effects of renin-angiotensin system (RAS) blockers. We investigated whether the phosphate binder sevelamer carbonate may enhance the antiproteinuric effect of RAS inhibitors in patients with CKD.Phase 2, randomized, controlled ...
Barbara Ruggiero, Matias Trillini, Lida Tartaglione, Silverio Rotondi, Elena Perticucci, Rocco Tripepi, Carolina Aparicio, Veruska Lecchi, Annalisa Perna, Francesco Peraro, Davide Villa, Silvia Ferrari, Antonio Cannata, Sandro Mazzaferro, Francesca Mallamaci, Carmine Zoccali, Antonio Bellasi, Mario Cozzolino, Giuseppe Remuzzi, Piero Ruggenenti, Donald E. Kohan, N. Perico, P. Ruggenenti, G. Remuzzi, N. Perico, B. Ruggiero, M. Trillini, C. Aparicio, L. Tartaglione, S. Rotondi, S. Prandini, V. Lecchi, D. Cugini, G. Gherardi, C. Zoccali, F. Mallamaci, G. Parlongo, V. Panuccio, G. Caridi, R. Tripepi, N. Rubis, O. Diadei, D. Villa, S. Carminati, D. Martinetti, G.A. Giuliano, A. Perna, F. Peraro, A. Celeste, F. Gaspari, F. Carrara, S. Ferrari, N. Stucchi, A. Cannata, S. Mazzaferro, L. Tartaglione, S. Rotondi, V. Fassino, P. Boccardo, S. Peracchi   +59 more
openaire   +5 more sources

Sevelamer Carbonate Markedly Reduces Levothyroxine Absorption

Endocrine‚ Metabolic & Immune Disorders-Drug Targets, 2014
We report the case of a young woman affected by hypothyroidism due to Hashimoto's thyroiditis, previously well compensated with a full replacement therapy (150 mcg/day of levothyroxine), presenting a clinical picture of myxedema, with a TSH=650 mU/L. Two years earlier she had started a dialysis treatment because of a chronic renal failure and had been ...
Iovino M, Iovine N, Petrosino A, Giagulli VA, Licchelli B, GUASTAMACCHIA, Edoardo, TRIGGIANI, Vincenzo   +6 more
openaire   +2 more sources

Sevelamer carbonate in the management of hyperphosphatemia

Therapy, 2008
Sevelamer carbonate appears to be a promising new agent in the control of serum phosphorus levels in subjects with chronic kidney disease. It contains the same active moiety as sevelamer hydrochloride, but has carbonate instead of chloride as the counterion.
L Kooienga, R Moore
openaire   +1 more source

A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis

Clinical Nephrology, 2007
Sevelamer carbonate is an anion exchange resin with the same polymeric structure as sevelamer hydrochloride in which carbonate replaces chloride as the anion. The study investigated the effects of sevelamer carbonate and sevelamer hydrochloride on serum phosphorus, lipids and bicarbonate levels in hemodialysis patients.This was a double-blind ...
J, Delmez, G, Block, J, Robertson, S, Chasan-Taber, A, Blair, M, Dillon, A J, Bleyer   +6 more
openaire   +2 more sources